- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07723664
Evaluation of SofWave Sofware-Guided Energy Delivery for Lower Face and Neck Rejuvenation
23. juli 2026 oppdatert av: Sofwave Medical LTD
Non-randomized single-arm prospective clinical study.
Studieoversikt
Status
Har ikke rekruttert ennå
Intervensjon / Behandling
Detaljert beskrivelse
Eligible subjects will receive 1 or 2 SofWave treatments (4-6 weeks apart) using the Total Treatment Energy (TTE) methods and will return to 3 follow up visits: at 4 weeks ± 2 weeks post last treatment (FU1), at 12 weeks ± 2 weeks post last treatment (FU2) , at 24 weeks ± 4 weeks post last treatment (FU3).
Studietype
Intervensjonell
Registrering (Antatt)
30
Fase
- Ikke aktuelt
Kontakter og plasseringer
Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.
Studiekontakt
- Navn: Shlomit Mann, MSc
- Telefonnummer: +972-4-7800268
- E-post: Shlomit@sofwave.com
Studer Kontakt Backup
- Navn: Ruthie Amir, MD
- Telefonnummer: +972-4-300-3164
- E-post: ruthie@sofwave.com
Studiesteder
-
-
Texas
-
Houston, Texas, Forente stater, 77004
- Dermatology & Laser Surgery Center
-
Hovedetterforsker:
- Paul Friedman, MD
-
Ta kontakt med:
- Paul Friedman, MD
- Telefonnummer: 713-900-3900
- E-post: drpaul@dermlasersurgery.com
-
-
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
- Voksen
Tar imot friske frivillige
Ja
Beskrivelse
Inclusion Criteria:
- Healthy female and male subjects between the ages 40-55.
- Non-Smoker.
- Fitzpatrick skin type I-VI.
- Desire to lift facial lax skin, neck and/or submental and/or improve facial wrinkles appearance.
- Presence of mild to moderate laxity in the lower face and submental area.
- Able and willing to comply with all visits, treatments and evaluation schedules and requirements.
- Able to understand and provide written Informed Consent.
- Women of child-bearing age are required to be using a reliable method of birth control at least 3 months prior to study enrollment.
- Subject agrees not to undergo any other facial cosmetic treatment for a period of 3 months following last SofWave treatment.
- Stable weight over the last 12 weeks and throughout the duration of the study.
- Subjects agree to adhere to safe sun practices and daily use of broad-spectrum sunscreen SPF 30+.
Male subjects with facial hair in the treatment area are willing to trim or shave as needed to allow consistent standardized photography.
-
Exclusion Criteria:
- Pregnant or planning to become pregnant, having given birth less than 3 months ago, and/or breast feeding.
- Presence of any active systemic or local infections.
- Open wounds or lesions within the intended to treat area.
- Tattoo or former tattoo at or near treatment area.
- Presence of active local skin disease that may alter wound healing.
- Uncontrolled diabetes mellitus.
- Skin cancer in the area to be treated. History of any other non-melanoma skin cancers in the past 5 years within the treatment area (head and neck).
- Severe solar elastosis.
- History of smoking in the past 10 years.
- History of chronic drug or alcohol abuse.
- Excessive subcutaneous fat on the cheeks.
- Significant scarring in the area to be treated or history of keloids.
- Severe or cystic facial acne, and/or Accutane use during the past 6 months.
- Pacemakers and electronic device implants in the treated area.
- Presence of a metal stent or implant in the facial area (dental implants and/or braces are not excluded).
- Inability to understand the protocol or to provide a signed informed consent.
History of cosmetic treatments in the area to be treated including:
- Chemical peels, microneedling, dermabrasion, energy-based devices, or laser treatments in the past 6 months
- Injectable filler treatments in the past 6 months
- Injectable neuromodulator treatment in the past 4 months
- Cosmetic surgical procedures in the treatment area, including but not limited to facelift in the past 12 months.
- Taking anti-platelet or anti-coagulant within the past 2 weeks.
- Ongoing use of psychiatric medication; taking psychiatric drugs within the past 2 weeks.
As per the investigator's discretion, any physical or mental condition which might make it unsafe for the subject to participate in this study.
-
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: N/A
- Intervensjonsmodell: Enkeltgruppeoppdrag
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Experimental: lax tissue
|
The Sofwave System, comprised of an applicator and a console, generates high intensity, non-focused ultrasonic energy which can be delivered percutaneously to tissues
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Evaluate the clinical efficacy of the treatment for lower face and upper neck rejuvenation
Tidsramme: 12 weeks post treatment follow-up visit
|
Rate of the Improvement in the appearance of lower face and upper neck rejuvenation following SofWave treatment based on Global Aesthetic Improvement Scale (-1=worse, 0=no change, 1=improved, 2=marked improvement, 3=very much improved)
|
12 weeks post treatment follow-up visit
|
|
Lower face and upper neck rejuvenation
Tidsramme: 12 weeks post treatment follow-up visit
|
Evaluate the clinical efficacy of the treatment for lower face and upper neck rejuvenation, as assessed by the study physician using Physician Global Aesthetic Improvement Scale (GAIS; (-1=worse, 0=no change, 1=improved, 2=marked improvement, 3=very much improved)) at 12 weeks follow-up visit.
|
12 weeks post treatment follow-up visit
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Sponsor
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart (Antatt)
20. juli 2026
Primær fullføring (Antatt)
15. juli 2027
Studiet fullført (Antatt)
15. juli 2027
Datoer for studieregistrering
Først innsendt
19. juli 2026
Først innsendt som oppfylte QC-kriteriene
19. juli 2026
Først lagt ut (Faktiske)
23. juli 2026
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
27. juli 2026
Siste oppdatering sendt inn som oppfylte QC-kriteriene
23. juli 2026
Sist bekreftet
1. juli 2026
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- SofWave31
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Nei
Studerer et amerikansk FDA-regulert enhetsprodukt
Ja
produkt produsert i og eksportert fra USA
Nei
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .